News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase
Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into
Cancer Centers Look to New NGS-Based ‘Frankenpanel’ to Get Fast Info on Clinically Actionable Genes
Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing
Pillar Biosciences to Present Impactful Research Data at 2024 Association for Molecular Pathology (AMP) Annual Meeting
Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit
Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory
Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina
Enables content for newly launched Illumina MiSeq™ i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels Natick, MA – October 16, 2024
Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing
Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions. Natick, MA